VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans

Cancer Gene Therapy

Volumn 23, Issue 5, 2016, Pages 125-132

  Kazemi, M ^a,c   Carrer, A ^a   Moimas, S ^a,b   Zandona L ^b   Bussani, R ^b   Casagranda, B ^b   Palmisano, S ^b   Prelazzi, P ^b   Giacca, M ^a,b   Zentilin, L ^a   De Manzini, N ^b   Zacchigna, S ^a,b  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 9; VASCULOTROPIN 121; VASCULOTROPIN 165; ISOPROTEIN; VASCULOTROPIN A;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER PATIENT; CELL CULTURE; CELL PROLIFERATION; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; LYMPH NODE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIBIALIS ANTERIOR MUSCLE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; DEPENDOPARVOVIRUS; DISEASE MODEL; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

ALTERNATIVE SPLICING; ANIMALS; CELL LINE, TUMOR; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; HYPOXIA; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84962106156     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2016.12     Document Type: Article

References (21)

1. Giacca M, Zacchigna S. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther 2012; 19: 622-629.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
3. Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M et al. Bone marrow cells recruited through the Neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis. J Clin Invest 2008; 118: 2062-2075.
4. Carrer A, Moimas S, Zacchigna S, Pattarini L, Zentilin L, Ruozi G et al. Neuropilin-1 identifies a subset of bone marrow Gr1-monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res 2012; 72: 6371-6381.
5. Misquitta-Ali CM, Cheng E, O'Hanlon D, Liu N, McGlade CJ, Tsao MS et al. Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Mol Cell Biol 2011; 31: 138-150.
6. Zhao YJ, Han HZ, Liang Y, Shi CZ, Zhu QC, Yang J. Alternative splicing of VEGFA, APP and NUMB genes in colorectal cancer. World J Gastroenterol 2015; 21: 6550-6560.
7. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148-154.
8. Arsic N, Zentilin L, Zacchigna S, Santoro D, Stanta G, Salvi S et al. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 2003; 7: 450-459.
9. Miles AA, Miles EM. Vascular reaction to histamine, histamine-liberator, and leu-kotaxine in the skin of guinea pigs. J Physiol 1952; 118: 228-257.
10. Zentilin L, Giacca M. Competitive PCR for precise nucleic acid quantification. Nat Protoc 2007; 2: 2092-2104.
11. Yoon C, Kim D, Kim S, Park GB, Hur DY, Yang JW et al. MiR-9 regulates the post-transcriptional level of VEGF165a by targeting SRPK-1 in ARPE-19 cells. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1369-1376.
12. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 2010; 21: 687-690.
13. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993; 91: 153-159.
14. Cai C, Bottcher MC, Werner JA, Mandic R. Differential expression of VEGF121, VEGF165 and VEGF189 in angiomas and squamous cell carcinoma cell lines of the head and neck. Anticancer Res 2010; 30: 805-810.
15. Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT et al. Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res 1995; 76: 758-766.
16. Salton M, Voss TC, Misteli T. Identification by high-throughput imaging of the histone methyltransferase EHMT2 as an epigenetic regulator of VEGFA alternative splicing. Nucleic Acids Res 2014; 42: 13662-13673.
17. Elias AP, Dias S. Microenvironment Changes (in pH) Affect VEGF Alternative Splicing. Cancer Microenviron 2008; 1: 131-139.
18. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10: 417-427.
19. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M et al. Semaphorin 3 A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 2009; 119: 3356-3372.
20. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010; 141: 178-190.
21. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64: 7822-7835.